Dayle Hogg
InvestorOperating Executive at Abingworth
About
Dayle Hogg joined Abingworth in March 2023 to support the operational capabilities of portfolio companies. He was previously COO of GammaDelta Therapeutics until its 2022 acquisition by Takeda, cofounder of Adaptate Biotherapeutics, COO of Kesios Therapeutics, and an investment manager at Touchstone Innovations, and he cofounded Lectus Therapeutics. He holds a degree in Pharmacology from the University of Leeds and a PhD in Pharmacology from the University of Oxford.
Invests in
Biotech
Investments
Led
Enterprise TherapeuticsStorm Therapeutics
Per the firm's website.
Colleagues at Abingworth
Alex Asquith
Counsel at Abingworth
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Abingworth
Diya Malhotra
Principal at Abingworth
Elizabeth O'Brien
Executive Assistant at Abingworth